[AG881-C-004]-laysummary-2024.01.05.he-IL

Home » A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation » [AG881-C-004]-laysummary-2024.01.05.he-IL

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.

Accessibility